Multimodal therapy and twenty years of valid management of a patient with chronic hepatitis B in a less developed Western Region in China---case report and review of the literature

Table 3 Cobas HBVDNA levels and Determination of lamivudine resistance sites

	HBVDNA manufactured in China	Cobas HBVDNA(IU/ml)	Determination of lamivudine resistance
	< 10³cps/ml	–	None
	< 10³cps/ml	–	None
2013–11	< 500 IU/ml	91	YMDD tolerance
2014–10	< 500 IU/ml	45	Can’t measure
2016–06	< 500 IU/ml	70	unmeasured
2017–12	< 500 IU/ml	76	unmeasured

ISSN: 1471-2334